fbpx

News

Novel HoloMonitor method identifies tumor creating cancer cells

Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.
Read More

PHI Launches Wound Healing Assay

HoloMonitor® Wound Healing Assay: The assay meets the unmet market demand of both quantifying cell movement automatically and in great detail. Wound healing assays are one of the most used laboratory methods to study cell movement. Conventional wound healing assays are either manual or just measure the collective movement of a cell population.
Read More

Leading Australian Research Institute Purchases HoloMonitor

A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation.
Read More

PHI and Malmö University receives 2.3 million SEK to detect blood-borne cancer cells

GlycoImaging is a collaboration project between PHI, Malmö University and four international research institutions. By combining PHI’s HoloMonitor technology with a new type of cancer probes, more sensitive methods to detect and diagnose cancer at an earlier stage than what is possible today.
Read More

Novel HoloMonitor based research to be presented at cancer research annual meeting

Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the novel research results.
Read More

Japan´s foremost medical institute purchases multiple HoloMonitor instruments

Japan’s foremost medical research institute, The Institute of Medical Science at University of Tokyo, recently purchased two HoloMonitor M4. Together with RIKEN and Kyoto University, the institute spearheads Japan’s national effort to become the undisputed leader of regenerative medicine in the world.
Read More

EU grants 2.1 million euro to Phase Holographic Imaging and Malmö University with partners for joint cancer research

The European Commission has appointed Phase Holographic Imaging,Bundesanstalt für Material-forschung und Prüfung (Germany’s federal technology research institute), Malmö, Umeå, Copenhagen and Turku University to develop improved methods for clinically diagnosing cancer.
Read More

American association of cancer research highlights article published by PHI collaborators

In the October issue of Molecular Cancer Therapeutics the American Association of Cancer Research (AACR) highlights the novel nano­medicine against ovarian cancer developed by scientists from the Center for Pharma­ceutical Bio­tech­nology and Nano­medicine at North­eastern University.
Read More

Lab of Nobel Price winner purchases HoloMonitor

The Department of Optical Nanoscopy (Prof. Stefan W. Hell) at the German Cancer Research Center (DKFZ) in Heidelberg recently ordered a motorized HoloMonitor M4. Professor Hell was awarded the Nobel Prize in Chemistry in 2014 for his pioneering work in the field of super-resolution fluorescence microscopy.
Read More

PHI receives significant order

PHI has received a follow-up order for a minimum of eight motorized HoloMonitor M4 instruments, continuing the strong business performance in the Chinese market. The total customer list price of the ordered instruments amounts to 2.8 MSEK. The instruments will be delivered to PHI’s Chinese distributor during the coming 12 months on a continuous basis. …
Read More